Donis Ruben O, Davis C Todd, Foust Angie, Hossain M Jaber, Johnson Adam, Klimov Alexander, Loughlin Rosette, Xu Xiyan, Tsai Theodore, Blayer Simone, Trusheim Heidi, Colegate Tony, Fox John, Taylor Beverly, Hussain Althaf, Barr Ian, Baas Chantal, Louwerens Jaap, Geuns Ed, Lee Min-Shi, Venhuizen Odewijk, Neumeier Elisabeth, Ziegler Thedi
Vaccine. 2014 Nov 12;32(48):6583-90. doi: 10.1016/j.vaccine.2014.06.045. Epub 2014 Jun 24.
Cell culture is now available as a method for the production of influenza vaccines in addition to eggs. In accordance with currently accepted practice, viruses recommended as candidates for vaccine manufacture are isolated and propagated exclusively in hens' eggs prior to distribution to manufacturers. Candidate vaccine viruses isolated in cell culture are not available to support vaccine manufacturing in mammalian cell bioreactors so egg-derived viruses have to be used. Recently influenza A (H3N2) viruses have been difficult to isolate directly in eggs. As mitigation against this difficulty, and the possibility of no suitable egg-isolated candidate viruses being available, it is proposed to consider using mammalian cell lines for primary isolation of influenza viruses as candidates for vaccine production in egg and cell platforms. To investigate this possibility, we tested the antigenic stability of viruses isolated and propagated in cell lines qualified for influenza vaccine manufacture and subsequently investigated antigen yields of such viruses in these cell lines at pilot-scale. Twenty influenza A and B-positive, original clinical specimens were inoculated in three MDCK cell lines. The antigenicity of recovered viruses was tested by hemagglutination inhibition using ferret sera against contemporary vaccine viruses and the amino acid sequences of the hemagglutinin and neuraminidase were determined. MDCK cell lines proved to be highly sensitive for virus isolation. Compared to the virus sequenced from the original specimen, viruses passaged three times in the MDCK lines showed up to 2 amino acid changes in the hemagglutinin. Antigenic stability was also established by hemagglutination inhibition titers comparable to those of the corresponding reference virus. Viruses isolated in any of the three MDCK lines grew reasonably well but variably in three MDCK cells and in VERO cells at pilot-scale. These results indicate that influenza viruses isolated in vaccine certified cell lines may well qualify for use in vaccine production.
除了利用鸡蛋生产流感疫苗外,细胞培养现已成为一种生产流感疫苗的方法。按照目前公认的做法,推荐作为疫苗生产候选毒株的病毒在分发给制造商之前,仅在鸡胚中分离和增殖。在细胞培养中分离的候选疫苗病毒无法用于支持哺乳动物细胞生物反应器中的疫苗生产,因此必须使用源自鸡蛋的病毒。最近,甲型H3N2流感病毒很难直接在鸡蛋中分离出来。为了缓解这一困难,并应对可能没有合适的从鸡蛋中分离出的候选病毒的情况,建议考虑使用哺乳动物细胞系对流感病毒进行初次分离,作为在鸡蛋和细胞平台上生产疫苗的候选毒株。为了研究这种可能性,我们测试了在符合流感疫苗生产资质的细胞系中分离和增殖的病毒的抗原稳定性,随后在中试规模下研究了这些细胞系中此类病毒的抗原产量。将20份甲型和乙型流感阳性原始临床标本接种到三种犬肾传代细胞系(MDCK)中。使用雪貂血清针对当代疫苗病毒通过血凝抑制试验检测回收病毒的抗原性,并测定血凝素和神经氨酸酶的氨基酸序列。结果证明,MDCK细胞系对病毒分离高度敏感。与从原始标本中测序的病毒相比,在MDCK细胞系中传代三次的病毒在血凝素中最多出现2个氨基酸变化。通过与相应参考病毒相当的血凝抑制效价也确定了抗原稳定性。在三种MDCK细胞系中的任何一种中分离的病毒在中试规模下在三种MDCK细胞和非洲绿猴肾细胞(VERO)中生长情况良好但存在差异。这些结果表明,在经疫苗认证的细胞系中分离的流感病毒很可能有资格用于疫苗生产。